Navigation Links
Mirixa Corporation and the APhA Foundation Form Partnership
Date:10/9/2008

APhA Foundation and NCPA Join Forces to Deliver Patient Care via Single

Platform, MirixaPro(SM)

RESTON, Va. and WASHINGTON, Oct. 9 /PRNewswire/ -- Mirixa Corporation and the American Pharmacists Association (APhA) Foundation, the creator of the Diabetes Ten City Challenge and a partner in the Asheville Project(R), jointly announced today that they will form a new partnership that will deliver all of APhA Foundation's HealthMapRx commercial programs via Mirixa. MirixaPro(SM) will be the platform of choice for all existing and future APhA Foundation commercial programs delivered through pharmacy.

This partnership joins the quality and reach of Mirixa-enabled patient care programs and services with the APhA Foundation's highly respected and nationally renowned employer-based disease management and wellness research efforts. Additionally, this enhanced alliance between the National Community Pharmacist Association (NCPA), which sponsors Mirixa, and the APhA Foundation represents a significant opportunity for the pharmacy community by providing enhanced opportunities to deliver patient care services.

"We are delighted to have earned the trust of the APhA Foundation and to be selected as their business partner and pharmacy platform of choice," expressed Rick Solano, Mirixa's Chief Executive Officer. "This partnership represents a significant step forward in enhancing pharmacy-based patient care and education services at the national level, and will help pharmacists improve consumer health and the quality of many lives," added Mr. Solano.

"This important collaboration between national pharmacist organizations has the tremendous potential to incentivize wellness, improve patient outcomes and manage costs, thereby addressing critical issues facing the U.S. healthcare system. The new partnership creates synergies that will provide enhanced service delivery and program offerings to current and future clients and responds to requests by our employer clients and pharmacists for integrated systems for patient care," said William Ellis, R.Ph., Executive Director and Chief Executive Officer of the APhA Foundation.

Mirixa will manage the new partnership and will begin integration and transition steps as soon as the partnership is finalized. All existing commercialized APhA Foundation programs will continue uninterrupted during the transition period. The APhA Foundation will continue to focus on its core mission to improve the quality of consumer health outcomes through demonstration projects, incentive grants, institutes and scholarship programs.

About the APhA Foundation

The American Pharmacists Association (APhA) Foundation, headquartered in Washington, D.C., is a non-profit organization affiliated with the American Pharmacists Association, the national professional society of pharmacists in the United States. The APhA Foundation has expertise in designing programs that seek to create a new medication use system in the United States where patients, pharmacists, physicians and other health care providers collaborate to dramatically improve the cost and quality of consumer health outcomes through the safe and effective use of medications. For additional information: http://www.aphafoundation.org.

About Mirixa

Mirixa Corporation, sponsored by the National Community Pharmacists Association (NCPA), is the leader in targeted patient care services delivered via the nation's largest pharmacy-based patient care network. Dedicated to improving patients' health, Mirixa enables the healthcare community to deliver patient care services through retail pharmacy. Mirixa's web-based clinical application, MirixaPro(SM), is used by pharmacists to deliver standardized patient care services. For more information, please visit http://www.Mirixa.com.

Contacts: Christine Ryba Lisa Miller

703.865.2041 703.838.2682

PR@Mirixa.com Lisa.Miller@ncpanet.org


'/>"/>
SOURCE Mirixa Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):